124 related articles for article (PubMed ID: 29562516)
1. Potential Novel Approaches to Understand the Pathogenesis and Treat Alzheimer's Disease.
Drummond E; Goñi F; Liu S; Prelli F; Scholtzova H; Wisniewski T
J Alzheimers Dis; 2018; 64(s1):S299-S312. PubMed ID: 29562516
[TBL] [Abstract][Full Text] [Related]
2. Future horizons in Alzheimer's disease research.
Wisniewski T; Drummond E
Prog Mol Biol Transl Sci; 2019; 168():223-241. PubMed ID: 31699317
[TBL] [Abstract][Full Text] [Related]
3. Innate Immunity Stimulation via Toll-Like Receptor 9 Ameliorates Vascular Amyloid Pathology in Tg-SwDI Mice with Associated Cognitive Benefits.
Scholtzova H; Do E; Dhakal S; Sun Y; Liu S; Mehta PD; Wisniewski T
J Neurosci; 2017 Jan; 37(4):936-959. PubMed ID: 28123027
[TBL] [Abstract][Full Text] [Related]
4. Alzheimer's disease: experimental models and reality.
Drummond E; Wisniewski T
Acta Neuropathol; 2017 Feb; 133(2):155-175. PubMed ID: 28025715
[TBL] [Abstract][Full Text] [Related]
5. Molecular and functional signatures in a novel Alzheimer's disease mouse model assessed by quantitative proteomics.
Kim DK; Park J; Han D; Yang J; Kim A; Woo J; Kim Y; Mook-Jung I
Mol Neurodegener; 2018 Jan; 13(1):2. PubMed ID: 29338754
[TBL] [Abstract][Full Text] [Related]
6. Alzheimer's Disease: Characterization of the Brain Sites of the Initial Tau Cytoskeletal Pathology Will Improve the Success of Novel Immunological Anti-Tau Treatment Approaches.
Rüb U; Stratmann K; Heinsen H; Seidel K; Bouzrou M; Korf HW
J Alzheimers Dis; 2017; 57(3):683-696. PubMed ID: 28269779
[TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein E in Alzheimer's disease: an update.
Yu JT; Tan L; Hardy J
Annu Rev Neurosci; 2014; 37():79-100. PubMed ID: 24821312
[TBL] [Abstract][Full Text] [Related]
8. A multifunctional therapeutic approach to disease modification in multiple familial mouse models and a novel sporadic model of Alzheimer's disease.
Luo J; Lee SH; VandeVrede L; Qin Z; Ben Aissa M; Larson J; Teich AF; Arancio O; D'Souza Y; Elharram A; Koster K; Tai LM; LaDu MJ; Bennett BM; Thatcher GR
Mol Neurodegener; 2016 Apr; 11():35. PubMed ID: 27129593
[TBL] [Abstract][Full Text] [Related]
9. Systems Biology Methods for Alzheimer's Disease Research Toward Molecular Signatures, Subtypes, and Stages and Precision Medicine: Application in Cohort Studies and Trials.
Castrillo JI; Lista S; Hampel H; Ritchie CW
Methods Mol Biol; 2018; 1750():31-66. PubMed ID: 29512064
[TBL] [Abstract][Full Text] [Related]
10. Past to Future: What Animal Models Have Taught Us About Alzheimer's Disease.
Martini AC; Forner S; Trujillo-Estrada L; Baglietto-Vargas D; LaFerla FM
J Alzheimers Dis; 2018; 64(s1):S365-S378. PubMed ID: 29504540
[TBL] [Abstract][Full Text] [Related]
11. The contribution of neuroinflammation to amyloid toxicity in Alzheimer's disease.
Minter MR; Taylor JM; Crack PJ
J Neurochem; 2016 Feb; 136(3):457-74. PubMed ID: 26509334
[TBL] [Abstract][Full Text] [Related]
12. Impaired autophagy and APP processing in Alzheimer's disease: The potential role of Beclin 1 interactome.
Salminen A; Kaarniranta K; Kauppinen A; Ojala J; Haapasalo A; Soininen H; Hiltunen M
Prog Neurobiol; 2013; 106-107():33-54. PubMed ID: 23827971
[TBL] [Abstract][Full Text] [Related]
13. Alzheimer's disease pathogenesis and therapeutic interventions.
Parihar MS; Hemnani T
J Clin Neurosci; 2004 Jun; 11(5):456-67. PubMed ID: 15177383
[TBL] [Abstract][Full Text] [Related]
14. Innate immune system and inflammation in Alzheimer's disease: from pathogenesis to treatment.
Serpente M; Bonsi R; Scarpini E; Galimberti D
Neuroimmunomodulation; 2014; 21(2-3):79-87. PubMed ID: 24557039
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
[TBL] [Abstract][Full Text] [Related]
16. Translation of Pre-Clinical Studies into Successful Clinical Trials for Alzheimer's Disease: What are the Roadblocks and How Can They Be Overcome?
Banik A; Brown RE; Bamburg J; Lahiri DK; Khurana D; Friedland RP; Chen W; Ding Y; Mudher A; Padjen AL; Mukaetova-Ladinska E; Ihara M; Srivastava S; Padma Srivastava MV; Masters CL; Kalaria RN; Anand A
J Alzheimers Dis; 2015; 47(4):815-43. PubMed ID: 26401762
[TBL] [Abstract][Full Text] [Related]
17. The interactions of p53 with tau and Aß as potential therapeutic targets for Alzheimer's disease.
Jazvinšćak Jembrek M; Slade N; Hof PR; Šimić G
Prog Neurobiol; 2018 Sep; 168():104-127. PubMed ID: 29733887
[TBL] [Abstract][Full Text] [Related]
18. Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease.
Sadowski MJ; Pankiewicz J; Scholtzova H; Mehta PD; Prelli F; Quartermain D; Wisniewski T
Proc Natl Acad Sci U S A; 2006 Dec; 103(49):18787-92. PubMed ID: 17116874
[TBL] [Abstract][Full Text] [Related]
19. Update on Alzheimer's Disease Therapy and Prevention Strategies.
Graham WV; Bonito-Oliva A; Sakmar TP
Annu Rev Med; 2017 Jan; 68():413-430. PubMed ID: 28099083
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
